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after the patient has stopped any antibiotic therapy for at least 4
weeks. If the midstream urine of the patient does not indicate any
urinary tract infection, a localization study should be performed.
Pathogens usually recognized as causing a chronic prostate
infection are the same as the traditional uropathogens (TP),
mainly E. coli, other Enterobacteriaceae, Pseudomonas aeruginosa,
and enterococci. But also non traditional pathogens (NTP) includ-
ing Gram-positive bacteria, such as staphylococci and streptococci,
and also ureaplasmas, mycoplasmas and especially Chlamydia tra-
chomatis (Skerk 2008). A gonococcal prostatitis may be fairly rare
and can be acute and chronic.
The ﬂuoroquinolones are recommended as drugs of choice in
chronic infection of the prostate, if the pathogens are susceptible,
because of their favourable prostate pharmacokinetics, which are
however different between the analogues. Clinical studieswith lev-
oﬂoxacin have shown, that our conventional dosage regimens may
have to be reconsidered in favour of higher dosages and probably
shorter treatment durations. In case of STI in addition macrolides
and tetracyclines may be included into the therapeutic armamen-
tarium.
In chronic pelvic pain syndrome (CPPS) where infection cannot
be found, phenotyping of the symptoms and a multimodal ther-
apy may be considered since such a complex syndrome may have
several underlying pathologies.
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Abstract: Every year cervical cancer affects around 528000
women and causes 266000 deaths worldwide with 80% of deaths
occurring in less developed countries with a concomitant 18-fold
difference in mortality occurring between developed and develop-
ing countries. Cervical cancers is caused by the Human Papilloma
Virus (HPV)with the oncogenic types 16 and 18 accounting for 70%
of invasive disease. Other cancers associated with HPV infection
include vaginal, vulvar, penile, oropharyngeal and anal cancers. In
addition, HPV types 6 and 11 cause anogenital warts and recurrent
respiratory papillomatosis. In 2009, the World Health Organisa-
tion issued the ﬁrst position paper on HPV vaccines, revised in
2014, in which it supported HPV vaccine introduction into national
immunization programmeswhere: ‘i) prevention of cervical cancer
and/or other HPV-related disease is a public health priority ii) the
introduction is programmatically feasible and economically sus-
tainable, and where iii) cost-effectiveness aspects have been duly
considered. They recommended that the primary target population
should be girls aged 9-13 years but that HPV vaccination ofmales is
not recommended as a priority, especially in resource-constrained
settings, as the available evidence indicates that the ﬁrst prior-
ity should be for cervical cancer reduction by timely vaccination
of young females and high coverage with each dose. In 2014 the
recommendations for HPV vaccine changed form a three dose to a
two-dose schedule.
In 2011 the Global Alliance on Vaccines and immunisation
(GAVI), tasked with supporting the introduction of new vac-
cines into the world’s poorest countries, approved support of HPV
vaccines introduction into GAVI eligible countries with the low
negotiated price of US$ 4.50 per dose compared to US$ 100 in high-
income countries. By 2015GAVI plans to support the immunisation
of approximately one million girls with HPV vaccines and by 2015
more than 30 million girls in less developed countries.
This presentationwill explore the reach, successes and epidemi-
ological impact of HPV vaccine introduction worldwide and will
consider some of the challenges such as the introduction of school
immunisationprogrammes, the immunisationof boys, and the con-
troversy around HPV vaccine introduction in India.
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Background: Integrons are versatile gene acquisition systems
commonly found in bacterial genomes. They are ancient elements
that are a hot spot for genomic complexity, generating phenotypic
diversity and shaping adaptive responses. Mobile gene cassettes
captured within integron arrays encompass a vast and diverse
pool of genetic novelty. These elements are able to capture and
express gene cassettes encoding antibiotic resistance. The main
aim of this study was to investigate the distribution of integrons in
multidrug resistant diarrheagenic E.coli isolates, to analyze the pos-
sible relationship between the antimicrobial resistances proﬁles,
